Risk Management for Materials and Components Used in Orally Inhaled and Nasal Drug Products.
Novartis Pharma, San Carlos, California, USA.
Cheryl L M
CL
Stults
Boehringer-Ingelheim, Ingelheim, Germany.
Gaby
G
Reckzuegel
Mannkind Corporation, Danbury, Connecticut, USA.
Arthur
A
Bailey
Merck & Co, Whitehouse Station, New Jersey, USA.
Jonathan
J
Petersen
3M Company, St. Paul, Minnesota, USA.
Lisa
L
Dick
Catalent, Morrisville/RTP, North Carolina, USA.
Thomas
T
Feinberg
Smithers Rapra, Shrewsbury, Shropshire, UK.
Andrew
A
Feilden
3M Company, St. Paul, Minnesota, USA.
Sara
S
Miller
Sunovion Pharmaceuticals, Marlborough, Massachusetts, USA.
James
J
Connors
Drinker Biddle & Reath, LLP, Washington, District of Columbia, 20005, USA. lee.nagao@dbr.com.
Lee M
LM
Nagao
D000280:Administration, Inhalation; D000281:Administration, Intranasal; D000818:Animals; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control*; D006801:Humans; D009330:Nebulizers and Vaporizers; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D019064:Product Packaging; D012308:Risk Management
D004364:Pharmaceutical Preparations
container closure systems; nasal products; orally inhaled products; packaging; risk management